Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 452 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone 100 MG Clear all
Withdrawn Not applicable Interventional

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

NCT01206998
View directory record Official record
Conditions
Labor, Premature
Interventions
Vaginal progesterone gel, Placebo vaginal gel
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Pregnenolone for the Treatment of Alcohol Use Disorder

NCT05781009
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

NCT01101438
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years to 74 Years
Enrollment
3,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional

Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02642939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Mifepristone
Drug
Lead sponsor
Check, Jerome H., M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Melrose Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Perimenopausal Effects of Estradiol on Reward Responsiveness

NCT02255175
View directory record Official record
Conditions
Perimenopausal Depression
Interventions
Estradiol, Progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Depot Medroxyprogesterone Acetate as Emergency Contraception

NCT03395756
View directory record Official record
Conditions
Emergency Contraception, Contraception
Interventions
Depot-Medroxyprogestereone Acetate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational

Quick Start of Highly Effective Contraception

NCT02076217
View directory record Official record
Conditions
IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions
Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

NCT02515110
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
Interventions
External Beam Radiation Therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational

Combined Hormone Replacement in Menstrually-Related Mood Disorders

NCT00005011
View directory record Official record
Conditions
Premenstrual Syndrome, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Transdermal Estrogen in Women With Anorexia Nervosa

NCT03875378
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Transdermal estrogen, Placebos
Drug
Lead sponsor
Pouneh K. Fazeli, MD
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

LATe Cerclage in High-risk Pregnancies (LATCH)

NCT06036446
View directory record Official record
Conditions
Premature Birth
Interventions
Cervical cerclage, Vaginal Suppository Progesterone
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

NCT00417885
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane, sunitinib malate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)

NCT01602679
View directory record Official record
Conditions
Female Reproductive Physiology
Interventions
oral micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

NCT00163020
View directory record Official record
Conditions
Preterm Birth
Interventions
17-alpha-hydroxyprogesterone caproate injectable, Placebo
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

NCT03097120
View directory record Official record
Conditions
Heart Disease
Interventions
0.625 mg of conjugated equine estrogen, 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, placebo tablets
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Blocking Mifepristone Action With Progesterone

NCT03774745
View directory record Official record
Conditions
Pregnancy, Unwanted
Interventions
Mifepristone 200 MG, micronized Progesterone, Placebo oral capsule
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

NCT04682353
View directory record Official record
Conditions
Contraception
Interventions
TV-46046, Depo-subQ Provera
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695
View directory record Official record
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

NCT06357442
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Results available

Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

NCT03498313
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

NCT00290251
View directory record Official record
Conditions
Leiomyoma
Interventions
ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 2, 2026, 2:22 AM EDT